Pioneering Low-Energy X-Ray Therapy ‘Papillon’ Approved for NHS Use, offering Hope to Rectal Cancer Patients
Table of Contents
A groundbreaking, low-energy X-ray treatment for rectal cancer, known as Papillon, has received the green light for use within the National Health service (NHS), potentially sparing numerous patients from invasive surgery and significantly improving their quality of life. The therapy, recommended by the National Institute for Health and care Excellence (NICE), offers a less debilitating alternative for individuals diagnosed with early-stage rectal cancer.
A Non-Surgical Option for Select Patients
Papillon is specifically indicated for fit rectal cancer patients with tumors measuring 3cm or smaller, who may opt to avoid surgery or are considered high-risk candidates for such procedures. This innovative approach utilizes a form of brachytherapy, carefully inserting an X-ray tube through the anus and into the rectum to deliver precise, low doses of radiation directly to the cancerous tissue. A key benefit of this non-surgical pathway is the potential to avoid a stoma – a surgically created opening in the abdomen connecting to the digestive system – which can substantially improve a patient’s overall well-being.NICE emphasized that avoiding a stoma “substantially improves” quality of life.
How Papillon Works: A Targeted Approach
The Papillon therapy operates on the principle of delivering highly focused radiation directly to the tumor, minimizing damage to surrounding healthy tissue.
Patient Success Story
One patient, who was 45 at the time of her diagnosis, shared her experience with the therapy. diagnosed with rectal cancer at 45, she faced the prospect of surgery and a permanent stoma. “That was devastating – I was just too young to have to go through that,” Price recounted. “I was offered the chance to join the clinical trial, and I decided to do it immediately.” Her prosperous treatment underscores the potential of Papillon to offer a more positive outcome for patients facing similar diagnoses.
Impact on the NHS and Future Outlook
Dr. Caroline Brammer, medical director at The Clatterbridge Cancer Center, highlighted the broader implications of the approval.”Prof Myint is a world authority on the Papillon technique and thousands of Clatterbridge patients have benefited from this non-surgical treatment over the decades,” she said. “It is heartening to know that many more patients across the NHS will now have the same chance.” The advancement is also expected to help reduce surgical waiting lists and associated costs for the NHS, while concurrently enhancing the quality of life for countless patients battling rectal cancer.
Professor Myint, now 77 and continuing his consultancy work, expressed a sense of fulfillment. “I feel that I have done my job and I can now hang up my gloves, but not until this treatment is embedded as the standard of care in the NHS and across the world.”
Understanding Colorectal cancer
Colorectal cancer,encompassing cancers of the rectum,bowel,and colon,remains a significant health concern in the UK,with over 41,000 new cases diagnosed annually. Recognizing the symptoms early is crucial for effective treatment.
Symptoms of bowel cancer, according to the NHS, may include:
- Changes in your poo, such as having softer poo, diarrhoea or constipation that is not usual for you
- Needing to poo more or less often then usual for you
- Blood in your poo, which may look red or black
- Bleeding from your bottom
- often feeling like you need to poo, even if you’ve just been to the toilet
- Tummy pain
- A lump in your tummy
- Bloating
- Losing weight without trying
- Feeling very tired or short of breath – these are signs of anaemia, which can be caused by bowel cancer.
The approval of Papillon represents a significant step forward in the fight against rectal cancer, offering a beacon of hope and a less invasive treatment option for eligible patients across the UK.
